News Sentiment

FBIOP sentiment intelligence

Fortress Biotech Inc Pref Series A news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 20.06 Week of 19 Jun 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

75/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

-3.1% over one week, +20.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 75/100 classification
One-week reaction -3.1% Price reacting lower
Trend fit Trend active 20.1% over four weeks
Fair value 95.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 36
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
newsline.com 6
Market source 6
TradingView 5
TradingKey 4
Stock Traders Daily 4
Seeking Alpha 2
Sahm 2
AD HOC NEWS 2

Event Lens

What the news is about

Classified themes
Earnings 22
Market update 18
Deals and strategy 2
Guidance 2
Balance sheet 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 47
TradingKey Direct company coverage

Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Fortress Biotech Inc (FBIO) has an earnings forecast score of 8.00, ranking 55th in the Pharmaceuticals industry. Analysts have set an average price target of $10.75, with most recommending a "Buy" trend for the stock. The expected revenue for the next quarter is $18.30M, and the

Tone
Neutral 50/100
Event
Earnings
Published
19 Jun 2026 06:40
Source
TradingKey
Quartr Direct company coverage

Fortress Biotech (FBIO) AGM 2026 Summary

Fortress Biotech's 2026 Annual General Meeting (AGM) was called to order by the Executive Chairman, President, and CEO. Key agenda items included the election of directors and the ratification of KPMG as the independent auditors for 2026, both of which were approved by shareholde

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 14:40
Source
Quartr
TradingKey Direct company coverage

Fortress Biotech Inc (FBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Fortress Biotech Inc's (FBIO) dividend and stock split history. It notes that no dividends have been distributed in the past five years. The article also details several stock merger events that occurred on October 9, 2023, with a 15:1 ratio.

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 07:40
Source
TradingKey
TradingKey Direct company coverage

Fortress Biotech Inc (FBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article details Fortress Biotech Inc (FBIO)'s revenue breakdown by business segment for FY2023, FY2023Q4, FY2022, FY2022Q4, FY2021, and FY2019. Key products like Targadox®, Exelderm®, and Ximino® are highlighted with their respective revenue figures and proportions. The repo

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 07:40
Source
TradingKey
Stock Traders Daily Direct company coverage

(FBIOP) Volatility Zones as Tactical Triggers

This article from Stock Traders Daily provides a technical analysis of Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP), highlighting a near-term neutral outlook despite mid and long-term strength. It presents AI-generated trading stra

Tone
Positive 65/100
Event
Guidance
Published
15 Jun 2026 04:40
Source
Stock Traders Daily
Stock Traders Daily Direct company coverage

Price-Driven Insight from (FBIOP) for Rule-Based Strategy

This article provides a price-driven analysis for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP), indicating a strong overweight bias across all horizons. It identifies compelling upside potential due to the absence of resist

Tone
Positive 74/100
Event
Market update
Published
04 Jun 2026 03:38
Source
Stock Traders Daily
Ad Hoc News Direct company coverage

Fortress Biotech Inc stock (US32015L1035): Nasdaq-listed biotech moves in low-volume trade ahead of next earnings update

Fortress Biotech Inc. (FBIO), a Nasdaq-listed biotech company, has experienced low-volume trading and modest price movements as investors await its next quarterly report. The company specializes in rare diseases and oncology, with its business model relying on commercial specialt

Tone
Neutral 50/100
Event
Earnings
Published
02 Jun 2026 10:32
Source
Ad Hoc News
Seeking Alpha Direct company coverage

Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? (FBIO)

Fortress Biotech (FBIO) currently holds $256 million in cash and $39 million in debt, creating a strong balance sheet after a recent windfall from a Menkes disease drug sale. This positions the company to easily pay off $16 million in deferred FBIOP preferred dividends, which cou

Tone
Positive 70/100
Event
Balance sheet
Published
29 May 2026 21:39
Source
Seeking Alpha
Stock Traders Daily Direct company coverage

(FBIOP) Price Dynamics and Execution-Aware Positioning

This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP) using AI models. It highlights strong sentiment supporting an overweight bias despite elevated downside risk, providing institutional trading strategies tai

Tone
Positive 71/100
Event
Market update
Published
24 May 2026 02:10
Source
Stock Traders Daily
Sahm Direct company coverage

Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference

Fortress Biotech, an innovative biopharmaceutical company, announced that its Chairman, President, and CEO, Lindsay A. Rosenwald, M.D., will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference on Wednesday, May 20, 2026, at 12:20 PM ET. The company foc

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 07:09
Source
Sahm
TradingView Direct company coverage

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

This article provides details about Fortress Biotech, Inc.'s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) on the Nasdaq Stock Market. It briefly mentions the availability of financial data, news, community insights, and technical analysis for this speci

Tone
Neutral 50/100
Event
Market update
Published
18 May 2026 05:39
Source
TradingView
TradingView Direct company coverage

Number of shareholders of Fortress Biotech, Inc. – NASDAQ:FBIO

This article provides details on the number of shareholders for Fortress Biotech, Inc. (NASDAQ:FBIO). It appears to be a stub or a placeholder, as the actual numbers for "Period," "Value," "Change," and "Change %" are explicitly missing from the content. The page also includes ge

Tone
Neutral 50/100
Event
Market update
Published
17 May 2026 16:39
Source
TradingView
AD HOC NEWS Direct company coverage

Fortress Biotech stock (US32015L1035): FDA setback hits Menkes drug while investors eye next catalysts

Fortress Biotech has faced a setback after the FDA declined to approve CUTX-101, a Menkes disease treatment from its subsidiary Cyprium Therapeutics. This regulatory decision has put pressure on the company's valuation and rare-disease pipeline, impacting speculative investors. D

Tone
Neutral 50/100
Event
Regulatory and legal
Published
16 May 2026 10:08
Source
AD HOC NEWS
Stock Titan Direct company coverage

Highbridge (FBIO) reports 2.73M warrant-backed shares, 7.8% stake

Highbridge Capital Management has filed an amended Schedule 13G, reporting beneficial ownership of 2.73 million Fortress Biotech (FBIO) shares, which are issuable upon the exercise of warrants. This accounts for a 7.8% stake in the company, based on 32.2 million outstanding share

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 10:38
Source
Stock Titan
Sahm Direct company coverage

Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Fortress Biotech announced strong financial results for Q1 2026, reporting a consolidated net income of $108.4 million, driven by the FDA approval of ZYCUBO® for Menkes disease and the subsequent sale of its Priority Review Voucher for $205 million. The company also highlighted p

Tone
Positive 80/100
Event
Earnings
Published
15 May 2026 09:10
Source
Sahm
10TV Direct company coverage

Fortress Biotech: Q1 Earnings Snapshot

Fortress Biotech Inc. (FBIO) reported strong financial results for its first quarter, with a net income of $110.4 million, or $2.82 per share. The biopharmaceutical company also recorded revenues of $16 million during the period. This financial snapshot was generated using data f

Tone
Neutral 50/100
Event
Earnings
Published
14 May 2026 21:50
Source
10TV
TradingView Direct company coverage

Fortress Biotech, Inc. 1Q 2026: Revenue $15.92M, Net income $110.37M, EPS $2.82— 10-Q Summary

Fortress Biotech, Inc. reported strong first-quarter 2026 results, with revenue growing to $15.92M and net income attributable to common stockholders skyrocketing to $110.37M, resulting in a diluted EPS of $2.82. This significant improvement from the previous year's loss was larg

Tone
Neutral 50/100
Event
Earnings
Published
14 May 2026 21:09
Source
TradingView
Stock Titan Direct company coverage

Fortress Biotech (NASDAQ: FBIO) turns Q1 2026 profit after $205M PRV sale

Fortress Biotech reported a significant turnaround in Q1 2026, achieving a net income of $108.4 million due to the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, which generated a $158.9 million gain. The company also saw increased net revenue to $16.0

Tone
Neutral 50/100
Event
Earnings
Published
14 May 2026 20:38
Source
Stock Titan
TradingView Direct company coverage

Fortress Biotech posts $108.4M net income in Q1 2026, revenue $16.0M

Fortress Biotech (FBIO) reported a significant Q1 2026 net income of $108.4 million, primarily driven by a $158.9 million gain from the sale of a priority review voucher. The company's consolidated net revenue reached $16.0 million, mainly from Journey Medical’s dermatology produ

Tone
Neutral 50/100
Event
Earnings
Published
14 May 2026 20:09
Source
TradingView
AD HOC NEWS Direct company coverage

Fortress Biotech stock (US32015L1035): Q1 earnings miss on revenue, but EMROSI shows momentum

Fortress Biotech (FBIO) reported its Q1 2026 earnings, missing revenue expectations at $6.3 million but showing strong growth in its dermatology asset, EMROSI, which saw prescription volumes reach approximately 30,000. The company narrowed its net loss to $2.2 million from $4.1 m

Tone
Neutral 50/100
Event
Earnings
Published
14 May 2026 10:09
Source
AD HOC NEWS
Stock Traders Daily Direct company coverage

(FBIOP) as a Liquidity Pulse for Institutional Tactics

This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP) using AI models. It highlights weak near-term sentiment but long-term strength, with support being tested. The analysis provides institutional trading strat

Tone
Positive 62/100
Event
Balance sheet
Published
13 May 2026 00:54
Source
Stock Traders Daily
TradingKey Direct company coverage

TradingKey

This page from TradingKey provides a detailed overview of Fortress Biotech Inc. (FBIO), including its stock price, market capitalization, and a navigation menu to various financial data, discussions, and analysis tools. It also offers information about TradingKey's services, such

Tone
Neutral 50/100
Event
Market update
Published
11 May 2026 20:09
Source
TradingKey